QIAGEN acquires Genoox to enhance genetic data analysis

VENLO, the Netherlands & TEL AVIV, Israel - QIAGEN (NYSE:QGEN; Frankfurt Prime Standard:QIA) has completed the acquisition of Genoox, an artificial intelligence (AI) software company, for a total consideration of $70 million and up to $10 million in additional milestone payments. This move aims to bolster QIAGEN’s portfolio in the rapidly growing market for clinical decision support in genetic diseases.

The acquisition introduces Franklin, Genoox’s cloud-based platform, to QIAGEN’s Digital Insights suite, enhancing the company’s capabilities in genetic data interpretation. This expansion builds on QIAGEN’s robust business model, which generated $2 billion in revenue over the last twelve months with an impressive 66.9% gross margin. Franklin’s AI-driven platform aids laboratories in processing next-generation sequencing (NGS) data, which is essential for diagnosing genetic disorders, informing cancer treatments, and aiding family planning decisions. The platform is currently employed by over 4,000 healthcare organizations across more than 50 countries and has contributed to over 750,000 case interpretations.

QIAGEN CEO Thierry Bernard expressed the significance of the acquisition, stating that Franklin’s AI-powered solution will enable clinical testing laboratories to rapidly identify clinically relevant insights, thus improving patient outcomes. The integration of Franklin with QIAGEN’s existing clinical knowledge and interpretation tools is expected to address customer challenges by providing scalable clinical decision-support solutions.

Amir Trabelsi, Co-founder and CEO of Genoox, also commented on the acquisition, highlighting the opportunity for Franklin to expand its impact through QIAGEN’s global reach and scientific leadership, driving advancements in precision medicine.

The transaction is expected to contribute approximately $5 million in sales for QIAGEN in 2025 and is anticipated to have a neutral impact on adjusted earnings per share (EPS). According to InvestingPro, eight analysts have recently revised their earnings estimates upward for the upcoming period, suggesting growing confidence in the company’s prospects. The acquisition also paves the way for the integration of QIAGEN’s genomic content, including the Human Gene Mutation Database (HGMD), the Catalogue of Somatic Mutations in Cancer (COSMIC), and the QIAGEN Knowledge Base (QKB), into the Franklin platform. For detailed analysis and additional insights, investors can access the comprehensive Pro Research Report available on InvestingPro, covering this and 1,400+ other top US stocks. These integrations are projected to enhance the platform’s interpretive power and, in turn, improve diagnostic yield, turnaround time, and scalability for clinical labs.

Genoox, founded in 2014 and based in Tel Aviv, Israel, specializes in cloud-based tools for genomic data interpretation in clinical and research settings. QIAGEN, headquartered in the Netherlands, is a leading provider of Sample to Insight solutions, serving over 500,000 customers globally across life sciences and molecular diagnostics.

The information provided in this article is based on a press release statement from QIAGEN N.V.

In other recent news, QIAGEN has raised its full-year 2025 earnings outlook, projecting an adjusted diluted earnings per share (EPS) of approximately $2.35, up from the earlier estimate of around $2.28. Preliminary results for the first quarter indicate an adjusted EPS of at least 55 cents, surpassing the Bloomberg Consensus estimate of 49 cents, with net sales at constant exchange rates reaching $483 million. Meanwhile, Redburn-Atlantic has downgraded QIAGEN’s stock rating from Buy to Neutral, lowering the price target from EUR47.00 to EUR41.00, due to revised revenue forecasts and a more mature growth trajectory for certain business segments. The analysts have adjusted their revenue estimates down by 2% to 4% for fiscal years 2025 through 2027, also reducing the adjusted EPS forecast by 2% to 5%. Additionally, QIAGEN has announced plans to propose an annual cash dividend of $0.25 per ordinary share, pending shareholder approval, which would result in an aggregate payout of approximately $54 million. This strategic move aims to balance shareholder returns with sustainable growth and creditworthiness. These developments reflect the company’s efforts to navigate market conditions and enhance operational efficiency.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.